These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 25213670

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M, Itamochi H, Kawaguchi W, Kudoh A, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T.
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [Abstract] [Full Text] [Related]

  • 24. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.
    Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP.
    PLoS One; 2012 Jul; 7(2):e30820. PubMed ID: 22319590
    [Abstract] [Full Text] [Related]

  • 25. Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
    Zhang T, Ma L, Wu P, Li W, Li T, Gu R, Dan X, Li Z, Fan X, Xiao Z.
    Oncol Rep; 2019 Mar; 41(3):1779-1788. PubMed ID: 30747218
    [Abstract] [Full Text] [Related]

  • 26. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Mar; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 27. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK, Zhang Y, Zhang ZJ, Qiu QW, Cao JG, He ZM.
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [Abstract] [Full Text] [Related]

  • 28. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, Shanmugam MK, Dai X, Li F, Deivasigamani A, Hui KM, Kumar AP, Lobie PE, Bender A, Basappa, Sethi G, Rangappa KS.
    J Biol Chem; 2014 Dec 05; 289(49):34296-307. PubMed ID: 25320076
    [Abstract] [Full Text] [Related]

  • 29. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
    Noori S, Nourbakhsh M, Farzaneh S, Zarghi A.
    Anticancer Agents Med Chem; 2020 Dec 05; 20(18):2285-2292. PubMed ID: 32767949
    [Abstract] [Full Text] [Related]

  • 30. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
    Zhang F, Shen M, Yang L, Yang X, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y.
    Cancer Biol Ther; 2017 Aug 03; 18(8):606-615. PubMed ID: 28686074
    [Abstract] [Full Text] [Related]

  • 31. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 03; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 32. Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance.
    Xiong J, Zhang X, Zhang Y, Wu B, Fang L, Wang N, Yi H, Chang N, Chen L, Zhang J.
    Exp Cell Res; 2020 Nov 01; 396(1):112288. PubMed ID: 32941808
    [Abstract] [Full Text] [Related]

  • 33. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z, Zhang Y, Li Y, Lv T, Liu J, Wang X.
    Acta Histochem; 2012 Feb 01; 114(2):151-8. PubMed ID: 21549414
    [Abstract] [Full Text] [Related]

  • 34. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y, Dong ZY, Wang JY.
    Eur Rev Med Pharmacol Sci; 2018 Aug 01; 22(15):4879-4887. PubMed ID: 30070323
    [Abstract] [Full Text] [Related]

  • 35. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Cancer Biol Ther; 2011 Nov 01; 12(9):837-45. PubMed ID: 21885917
    [Abstract] [Full Text] [Related]

  • 36. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
    Hu Y, Dong XZ, Liu X, Liu P, Chen YB.
    Mol Pharm; 2016 Feb 01; 13(2):689-97. PubMed ID: 26685983
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.